Wells Fargo & Company Solid Biosciences Inc. Call Options Transaction History

Wells Fargo & Company

  • $434 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding SLDB

# of Institutions
2
Shares Held
97
Call Options Held
0
Put Options Held
0
View Full List

About Solid Biosciences Inc.

SLDB Quotes by TradingView
  • Ticker SLDB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,533,080
  • Market Cap $29.8M
  • Description
  • Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...
More about SLDB
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email